Tonix Pharmaceuticals Holding Corp.
TNXPTonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing treatments for central nervous system (CNS) disorders, immunology, and infectious diseases. The company specializes in using its proprietary technology platforms to develop novel therapies for conditions such as neurological disorders, grief, fibromyalgia, and COVID-19.
Company News
Tonix Pharmaceuticals received FDA clearance to proceed with a Phase 2 HORIZON study of TNX-102 SL, a potential new treatment for major depressive disorder, targeting 360 patients across 30 U.S. sites with planned enrollment in mid-2026.
Pharmaceutical companies are advancing treatments for rare diseases, with Soligenix leading efforts in developing HyBryte, a promising therapy for cutaneous T-cell lymphoma (CTCL), a rare skin cancer affecting older adults.
The biotechnology sector has experienced significant volatility, with Tonix Pharmaceuticals and Lexeo Therapeutics seeing major stock price surges. These surges were driven by positive regulatory updates and financial results, respectively, indicating potential long-term value for these companies.
Shares of Tonix Pharmaceuticals fell Tuesday after the company said it would discontinue development of its treatment for major depressive disorder.
Investors often rely on stock market news to stay abreast of everything,… The post Penny Stocks To Buy? 5 To Watch With Big News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
